Daily Archives: July 30, 2014

Gilead, sofosbuvir, and hepatitis C . . . We’re reading about the high cost of living

By on .

The Treatment Action Group’s 2014 Pipeline Report released in conjunction with the 20th International AIDS Conference last week devotes three sections to the outlook for better and more accessible treatment for hepatitis C, examining the promise of new direct acting antiviral treatments, starting with sofosbuvir (marketed by Gilead pharmaceutical company as Sovaldi) being eclipsed by […]